Table 4.

Summary of agents used in published reports (6, 7, 11–23) for Treatment of MIS-C.

Treatment	% Usage (n)
Intravenous immunoglobulin (IVIG)	77.7% (198/255)
2nd Dose IVIG	17.1% (19/111)
Steroids	61.6% (157/255)
Aspirin	41.8% (71/170)
Anakinra	9.6% (24/251)
Tocilizumab	11.0% (28/255)
Infliximab	3.2% (8/251)
Anticoagulation (enoxaparin, etc.)	63.3 (133/210)
Antibiotics	87.7 (50/57)